Volumetric assessment of all PET-positive lesions before radioligand therapy has already proven impact on overall survival (OS) in prostate cancer patients undergoing prostate-specific membrane antigen (PSMA) therapy [42]. The gene discussed is FOLH1; the disease is prostate cancer.